Literature DB >> 7849267

The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue.

J T Isaacs1, Y Furuya, R Berges.   

Abstract

Cells possess within their repertoire of epigenetic programs the ability to undergo a process of cellular suicide, termed programmed cell death. This programmed cell death process involves an epigenetic reprogramming of the cell that results in an energy-dependent cascade of biochemical and morphologic changes within the cell (also termed apoptosis), resulting in its death and elimination. Although the final steps (i.e. DNA and cellular fragmentation) are common to cells undergoing programmed death, the activation of this death process is initiated either by sufficient injury to the cell induced by various exogenous damaging agents (e.g. radiation, chemicals, viruses, etc) or by changes in the levels of a series of endogenous signals (e.g. hormones and growth/survival factors). As an illustrative example, the role of androgen as a cell type specific endogenous regulator of the programmed death of normal and neoplastic prostatic cells will be presented.

Mesh:

Substances:

Year:  1994        PMID: 7849267

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  24 in total

Review 1.  Gene targeting to the stroma of the prostate and bone.

Authors:  Roger S Jackson; Omar E Franco; Neil A Bhowmick
Journal:  Differentiation       Date:  2008-05-20       Impact factor: 3.880

2.  Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.

Authors:  Mohamed S Arredouani; Stephanie S Tseng-Rogenski; Brent K Hollenbeck; June Escara-Wilke; Karen R Leander; Deborah Defeo-Jones; Clara Hwang; Martin G Sanda
Journal:  Prostate       Date:  2010-06-15       Impact factor: 4.104

3.  c-Jun NH2-terminal kinase-induced proteasomal degradation of c-FLIPL/S and Bcl2 sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine.

Authors:  Pankaj Chaudhary; Jamboor K Vishwanatha
Journal:  Biochem Pharmacol       Date:  2014-08-30       Impact factor: 5.858

4.  Dr. Coffey's visionary contributions to urological research in China and Japan.

Authors:  Jun Shimazaki; Leland Wk Chung; Haiyen E Zhau; Tomohiko Ichikawa
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

5.  T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

Authors:  M Mercader; B K Bodner; M T Moser; P S Kwon; E S Park; R G Manecke; T M Ellis; E M Wojcik; D Yang; R C Flanigan; W B Waters; W M Kast; E D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

6.  Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.

Authors:  Zhuangzhuang Zhang; Lijun Cheng; Jie Li; Elia Farah; Nadia M Atallah; Pete E Pascuzzi; Sanjay Gupta; Xiaoqi Liu
Journal:  Cancer Res       Date:  2018-04-26       Impact factor: 12.701

7.  Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells.

Authors:  Joanna Nightingale; Khurram S Chaudhary; Paul D Abel; Andrew P Stubbs; Hanna M Romanska; Stephen E Mitchell; Gordon W H Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

8.  Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate.

Authors:  Fei Su; Bruna R S Correa; Jianhua Luo; Ricardo Z N Vencio; Laura E Pascal; Zhou Wang
Journal:  Cancer Microenviron       Date:  2013-02-26

9.  Androgen-Sensitized Apoptosis of HPr-1AR Human Prostate Epithelial Cells.

Authors:  Congcong Chen; Jason A Dienhart; Eric C Bolton
Journal:  PLoS One       Date:  2016-05-20       Impact factor: 3.240

10.  The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.

Authors:  Steven Kregel; Russell Z Szmulewitz; Donald J Vander Griend
Journal:  Prostate       Date:  2014-08-31       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.